After a formal review, the US Department of Health and Human Services (HHS) recommended the US Drug Enforcement Agency (DEA) reclassify cannabis to a Schedule 3 drug rather than a Schedule 1 drug. Currently, cannabis is classified in the same category as heroin and other highly addictive drugs that have a high risk of fatal…
Many in the Industry Disappointed by Lack of Guidance in Key Areas – LPC The much-anticipated US Food and Drug Administration (FDA) draft guidance for the cannabis industry was released on July 21. The nine-page document is officially titled “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry”. It covers sources…
New Research Studies Effects of Availability on the OTC Sleep Aid Market – LPC New research out of Colorado seems to indicate that many people are using recreational cannabis to treat insomnia. The research methods the researchers used are unique – and perhaps ingenious. Scientists from the University of New Mexico and California State Polytechnic…
US and Canadian Scientists Call for All Cannabis Research Restrictions to Be Lifted – LPC Three scientists from Canada and the US are calling for cannabis research restrictions to be lifted. They state that these restrictions are unnecessary, perpetuate stigma, and are ultimately a danger to public health. “We think these restrictions require a…
Strict Rules and a Forced Hand May Result in All Applications to Cultivate Cannabis Rejected – LPC The US Drug Enforcement Agency (DEA) said that it will review dozens of applications to cultivate cannabis for research purposes. This after many years of delay for some applications – a delay that ended with a court…
Research Still Needed into CBD Remedies, but Facts So Far Are Encouraging – LPC When it comes to CBD remedies, it’s difficult to decide who is right and who is wrong. You hear all these “miracle” stories about how cannabis cured this disease and relieved those symptoms. But then you hear from doctors who say…
